A novel treatment option in rheumatoid arthritis: Abatacept, a selective modulator of T-cell co-stimulation

被引：2
作者：
Dejaco C. [1 ]
Duftner C. [1 ]
Wipfler E. [1 ]
Schirmer M. [1 ,2 ]
机构：
[1] Abteilung für Innere Medizin, Krankenhaus der Elisabethinen, Klagenfurt
[2] Abteilung FürInnere Medizin, Krankenhaus der Elisabethinen, 9020 Klagenfurt
来源：
Wiener Medizinische Wochenschrift | 2009年 / 159卷 / 3-4期
关键词：
Abatacept; Biologics; Rheumatoid arthritis;
D O I：
10.1007/s10354-008-0590-3
中图分类号：
学科分类号：
摘要：
Abatacept is the first drug in a new class of disease-modifying anti-rheumatic drugs known as selective modulators of T-cell costimulation. The efficacy of abatacept in the treatment of rheumatoid arthritis (RA) has been shown in several clinical phase II and phase III trials, wherein abatacept was used in monotherapy, either in combination with methotrexate (MTX) after MTX-failure, in combination with MTX after failure of anti-TNF-α therapy or in combination with TNF-α blockers. In addition, the combination of abatacept/MTX was directly compared with infliximab/MTX. Current data on abatacept demonstrate an encouraging safety profile of this drug. The number of adverse events in patients on abatacept is comparable to that in patients treated with other biologics. Severe infections, however, are more common in abatacept-treated patients than in placebo-treated patients. Opportunistic infections are rare in patients with abatacept and the frequency of malignancies is not higher than expected in RA-patients. Additional studies are now warranted to get more information on rare adverse events and long-term unwanted effects. © 2009 Springer-Verlag.
引用
收藏
页码：70 / 75
页数：5
相关论文
共 38 条
[1]  
Smolen J.S., Aletaha D., Koeller M., Weisman M.H., Emery P., New therapies for treatment of rheumatoid arthritis, Lancet, 370, pp. 1861-1874, (2007)
[2]  
Pope R.M., Perlman H., (1999)
[3]  
Ruderman E.M., Pope R.M., Drug Insight: Abatacept for the treatment of rheumatoid arthritis, Nat Clin Pract Rheumatol, 2, pp. 654-660, (2006)
[4]  
Salomon B., Bluestone J.A., Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation, Annu Rev Immunol, 19, pp. 225-252, (2001)
[5]  
Harding F.A., McArthur J.G., Gross J.A., Raulet D.H., Allison J.P., CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones, Nature, 356, pp. 607-609, (1992)
[6]  
Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., Ledbetter J.A., CTLA-4 is a second receptor for the B cell activation antigen B7, J Exp Med, 174, pp. 561-569, (1991)
[7]  
Walunas T.L., Bakker C.Y., Bluestone J.A., CTLA-4 ligation blocks CD28-dependent T cell activation, J Exp Med, 183, pp. 2541-2550, (1996)
[8]  
Karandikar N.J., Vanderlugt C.L., Walunas T.L., Miller S.D., Bluestone J.A., CTLA-4: A negative regulator of autoimmune disease, J Exp Med, 184, pp. 783-788, (1996)
[9]  
Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H., Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4, Immunity, 3, pp. 541-547, (1995)
[10]  
Bluestone J.A., St Clair E.W., Turka L.A., CTLA4Ig: Bridging the basic immunology with clinical application, Immunity, 24, pp. 233-238, (2006)
1234